S15176 and S16950 interaction with Cyclosporin A antiproliferative effect on cultured human lymphocytes

Fundamental and Clinical Pharmacology

Volumn 15, Issue 1, 2001, Pages 41-46

  Albengres, Edith ^a   Louët, Hervé Le ^a   D'Athis, Philippe ^b   Tillement, Jean Paul ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Cyclosporin A; Immunosuppressive activity; S16950; SI5176

Indexed keywords

CYCLOSPORIN A; S 15176; S 16950; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CELL HYPOXIA; CLINICAL ARTICLE; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIOXIDANTS; CALCIUM; CELLS, CULTURED; CYCLOSPORINE; DNA FRAGMENTATION; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MALE; MITOCHONDRIA; PIPERAZINES; THYMIDINE; TRIMETAZIDINE;

EID: 0035041097     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2001.00001.x     Document Type: Article

References (10)

1. Action of cyclosporin on mitochondrial calcium fluxes
2. Potential interest of anti-ischemic agents for limiting cyclosporin A nephrotoxicity
3. Trimetazidine reverses calcium accumulation and impairment of ATP synthesis induced by cyclosporin A in isolated rat liver mitochondria
4. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function
5. Trimetazidine reverses deleterious effects of ischemia-reperfusion in the isolated perfused pig kidney model
6. S-15176 reduces the hepatic injury in rats subjected to experimental ischemia and reperfusion
7. Onset and development of cyclosporin A effects on lymphocytes of cardiac patients before heart transplantation
8. A simple salting out procedure for extracting DNA from human nucleated cells
9. ++-dependant mitochondrial swelling
10. Lack of pharmacodynamic interaction between trimetazidine and cyclosporin A in human lymphoproliferative and mouse delayed hypersensitivity response models